Eiger BioPharmaceuticals' Core ValuesWe are a values-driven company that works to embody Integrity, Passion, Accountabilitity, Creativity, and Teamwork in the pursuit of our mission.
SpotlightThe Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus (HDV) Infected Patients
Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) – Results Presented at European Association for the Study of the Liver (EASL) Meeting in Vienna, Austria
In the NewsEiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs: Dr Joanne Quan, M.D., as Chief Medical Officer & Dr Shelly Xiong, Ph.D., as Vice President of Regulatory Affairs
Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for Hepatitis Delta Virus (HDV) Infection